OBI Pharma Announces Poster Presentations at the AACR 2025 Annual Meeting for OBI-992 and OBI-902 Antibody-Drug Conjugates (ADCs),
GlycOBI® and ThiOBI® ADC enabling technologies, the OBI-3424 prodrug, and Globo H (GH) science.

Poster Presentations featuring the latest advancements on anti-TROP2 ADCs (OBI 992 and OBI 902), AKR1C3 prodrug (OBI-3424), OBI’s novel ADC enabling technologies (GlycOBI® and ThiOBI®), and Globo H science.

HOMEWhat’s NewNewsOBI Pharma Announces Poster Presentations at the AACR 2025 Annual Meeting for OBI-992 and OBI-902 Antibody-Drug Conjugates (ADCs), GlycOBI® and ThiOBI® ADC enabling technologies, the OBI-3424 prodrug, and Globo H (GH) science.

Back to List

This article is password protected.

To view the content, please enter your password in the field below

2025.Mar.28

GlycOBI® Advances Bispecific and Dual Payload ADC Development OBI Demonstrates Innovations at the Novel Conjugates Summit in Boston